Yes. Mice don't get endogenous Lewy Body disease. The mouse model in the study is derived by injecting α-Syn preformed fibrils into the striatum. Whether SAK3 application will translate into human LBD treatments might depend on other aspects of the human disease process. With that understanding, the next step is to give it a go in human trials.
I'm sure they'll have no shortage of volunteers. It's the only game in town, and LBD patients have nothing to lose.
Yes. Mice don't get endogenous Lewy Body disease. The mouse model in the study is derived by injecting α-Syn preformed fibrils into the striatum. Whether SAK3 application will translate into human LBD treatments might depend on other aspects of the human disease process. With that understanding, the next step is to give it a go in human trials.
I'm sure they'll have no shortage of volunteers. It's the only game in town, and LBD patients have nothing to lose.